1. Home
  2. TRDA vs MTLS Comparison

TRDA vs MTLS Comparison

Compare TRDA & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRDA
  • MTLS
  • Stock Information
  • Founded
  • TRDA 2016
  • MTLS 1990
  • Country
  • TRDA United States
  • MTLS Belgium
  • Employees
  • TRDA N/A
  • MTLS N/A
  • Industry
  • TRDA Biotechnology: Pharmaceutical Preparations
  • MTLS Computer Software: Prepackaged Software
  • Sector
  • TRDA Health Care
  • MTLS Technology
  • Exchange
  • TRDA Nasdaq
  • MTLS Nasdaq
  • Market Cap
  • TRDA 350.5M
  • MTLS 389.8M
  • IPO Year
  • TRDA 2021
  • MTLS 2014
  • Fundamental
  • Price
  • TRDA $9.92
  • MTLS $5.91
  • Analyst Decision
  • TRDA Strong Buy
  • MTLS
  • Analyst Count
  • TRDA 2
  • MTLS 0
  • Target Price
  • TRDA $24.50
  • MTLS N/A
  • AVG Volume (30 Days)
  • TRDA 293.9K
  • MTLS 175.2K
  • Earning Date
  • TRDA 11-06-2025
  • MTLS 10-28-2025
  • Dividend Yield
  • TRDA N/A
  • MTLS N/A
  • EPS Growth
  • TRDA N/A
  • MTLS N/A
  • EPS
  • TRDA N/A
  • MTLS 0.09
  • Revenue
  • TRDA $61,520,000.00
  • MTLS $308,751,613.00
  • Revenue This Year
  • TRDA N/A
  • MTLS $2.47
  • Revenue Next Year
  • TRDA N/A
  • MTLS $6.98
  • P/E Ratio
  • TRDA N/A
  • MTLS $67.87
  • Revenue Growth
  • TRDA N/A
  • MTLS N/A
  • 52 Week Low
  • TRDA $4.93
  • MTLS $3.93
  • 52 Week High
  • TRDA $21.79
  • MTLS $9.69
  • Technical
  • Relative Strength Index (RSI)
  • TRDA 76.59
  • MTLS 48.65
  • Support Level
  • TRDA $8.17
  • MTLS $5.82
  • Resistance Level
  • TRDA $9.12
  • MTLS $6.40
  • Average True Range (ATR)
  • TRDA 0.72
  • MTLS 0.32
  • MACD
  • TRDA 0.20
  • MTLS -0.03
  • Stochastic Oscillator
  • TRDA 87.16
  • MTLS 36.73

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

Share on Social Networks: